Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer.

Wang N, Zhang H, Yao Q, Wang Y, Dai S, Yang X.

J Exp Clin Cancer Res. 2012 Jan 16;31:6. doi: 10.1186/1756-9966-31-6.

2.

Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer.

Kang S, Dong SM, Park NH.

Gynecol Oncol. 2010 Jul;118(1):58-63. doi: 10.1016/j.ygyno.2010.03.025. Epub 2010 Apr 24.

PMID:
20421128
3.

Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer.

Zhang H, Zhang S, Cui J, Zhang A, Shen L, Yu H.

Aust N Z J Obstet Gynaecol. 2008 Oct;48(5):505-9. doi: 10.1111/j.1479-828X.2008.00892.x.

PMID:
19032668
4.

ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.

Tumbarello DA, Temple J, Brenton JD.

Mol Cancer. 2012 May 28;11:36. doi: 10.1186/1476-4598-11-36.

5.
6.

Epigenetic regulation of putative tumor suppressor TGFBI in human leukemias.

Fang H, Liu J, Guo D, Liu P, Zhao Y.

Chin Med J (Engl). 2014;127(9):1645-50.

PMID:
24791868
7.

Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR.

Shah JN, Shao G, Hei TK, Zhao Y.

BMC Cancer. 2008 Oct 3;8:284. doi: 10.1186/1471-2407-8-284.

8.

XAF1 is frequently methylated in human esophageal cancer.

Chen XY, He QY, Guo MZ.

World J Gastroenterol. 2012 Jun 14;18(22):2844-9. doi: 10.3748/wjg.v18.i22.2844.

9.

RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines.

Zhang S, Wei L, Zhang A, Zhang L, Yu H.

OMICS. 2009 Aug;13(4):307-11. doi: 10.1089/omi.2009.0030.

PMID:
19645591
10.

Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.

Gao S, Zhao X, Lin B, Hu Z, Yan L, Gao J.

Tumour Biol. 2012 Oct;33(5):1759-65. doi: 10.1007/s13277-012-0435-y. Epub 2012 Jun 10.

PMID:
22684772
11.

Clinical importance and therapeutic implication of E-cadherin gene methylation in human ovarian cancer.

Wu X, Zhuang YX, Hong CQ, Chen JY, You YJ, Zhang F, Huang P, Wu MY.

Med Oncol. 2014 Aug;31(8):100. doi: 10.1007/s12032-014-0100-y. Epub 2014 Jun 29.

PMID:
24973953
12.

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.

Ribeiro JR, Schorl C, Yano N, Romano N, Kim KK, Singh RK, Moore RG.

J Ovarian Res. 2016 May 17;9(1):28. doi: 10.1186/s13048-016-0240-0.

13.

Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.

Ho CM, Huang CJ, Huang SH, Chang SF, Cheng WF.

BMC Cancer. 2015 Oct 24;15:789. doi: 10.1186/s12885-015-1744-5.

14.

Mismatch repair and treatment resistance in ovarian cancer.

Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G, Berns EM.

BMC Cancer. 2006 Jul 31;6:201.

15.

Decreased expression of RIZ1 and its clinicopathological significance in epithelial ovarian carcinoma: correlation with epigenetic inactivation by aberrant DNA methylation.

Akahira J, Suzuki F, Suzuki T, Miura I, Kamogawa N, Miki Y, Ito K, Yaegashi N, Sasano H.

Pathol Int. 2007 Nov;57(11):725-33.

PMID:
17922684
16.

Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.

Li Y, Chen K, Li L, Li R, Zhang J, Ren W.

Tumour Biol. 2015 Dec;36(12):9823-8. doi: 10.1007/s13277-015-3561-5. Epub 2015 Jul 11.

PMID:
26159849
17.

Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.

Lee C.

Mol Med Rep. 2015 Jul;12(1):1485-92. doi: 10.3892/mmr.2015.3542. Epub 2015 Mar 24.

PMID:
25815442
18.

Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma.

Ho CM, Huang CJ, Huang CY, Wu YY, Chang SF, Cheng WF.

Mol Cancer. 2012 Aug 8;11:53. doi: 10.1186/1476-4598-11-53.

19.

Identification of aberrant promoter hypomethylation of HOXA10 in ovarian cancer.

Cheng W, Jiang Y, Liu C, Shen O, Tang W, Wang X.

J Cancer Res Clin Oncol. 2010 Aug;136(8):1221-7. doi: 10.1007/s00432-010-0772-4. Epub 2010 Feb 12.

PMID:
20151152
20.

Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.

Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R.

Oncogene. 2012 Oct 18;31(42):4567-76. doi: 10.1038/onc.2011.611. Epub 2012 Jan 16.

PMID:
22249249

Supplemental Content

Support Center